Dyadic International (DYAI) Change in Accured Expenses (2018 - 2026)
Dyadic International (DYAI) posted Change in Accured Expenses of $98688.0 for Q1 2026, up 124.4% sequentially from -$404390.0 in Q4 2025, and up 305.68% YoY from $24326.7 in Q1 2025.
Dyadic International (DYAI) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Dyadic International has reported Change in Accured Expenses for 9 years, with the latest figure at $98688.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 305.68% year-over-year to $98688.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375802.0 (up 665.44% YoY) and the FY2025 annual result came in at $229132.0, down 9.31% from the prior year.
- Change in Accured Expenses improved to $98688.0 in Q1 2026 per DYAI's latest filing, from -$404390.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $691174.0 in Q2 2022 and troughed at -$404390.0 in Q4 2025.
- A 5-year average of $74722.0 and a median of $46441.0 in 2023 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1519.36% in 2025, down 408.6% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$32810.0 in 2022, then surged by 1431.67% to $436922.0 in 2023, then sank by 70.01% to $131041.0 in 2024, then sank by 408.6% to -$404390.0 in 2025, then soared by 124.4% to $98688.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $98688.0, -$404390.0, and $442513.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 98,688.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98,688.00 |
| Mar 31, 2026 | 98,688.00 |
| Dec 31, 2025 | -404,390.00 |
| Dec 31, 2025 | -404,390.00 |
| Sep 30, 2025 | 442,513.00 |
| Sep 30, 2025 | 442,513.00 |
| Jun 30, 2025 | 238,991.00 |
| Jun 30, 2025 | 238,991.00 |
| Mar 31, 2025 | -47,982.00 |
| Mar 31, 2025 | -47,982.00 |
| Dec 31, 2024 | 131,041.00 |
| Dec 31, 2024 | 131,041.00 |
| Sep 30, 2024 | -31,177.00 |
| Sep 30, 2024 | -31,177.00 |
| Jun 30, 2024 | -118,344.00 |
| Jun 30, 2024 | -118,344.00 |
| Mar 31, 2024 | 271,144.00 |
| Mar 31, 2024 | 271,144.00 |
| Dec 31, 2023 | 436,922.00 |
| Dec 31, 2023 | 436,922.00 |